Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

3rd Immunotherapy of Cancer Conference (ITOC3) /
Rationale for combining immunotherapy with chemotherapy

21st - 23rd Mar 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.04.16
Views: 1661
Rating:

Prof Angus Dalgleish - St. Georges University, London UK

Prof Angus Dalgliesh speaks with ecancertv at ITOC3 about his ongoing research in combined cancer therapies.

Prof Dalgliesh proposes that combinations of immunotherapy with other treatment modalities improves patient recovery, treatment response rates and affordability of care.

He discusses improved immune response and sensitivity following 'priming' of patients with immune modulators, and following intermittent treatment administration compared to continuous therapy.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation